There have been reports of relapse after cessation of lamivudine monotherapy for hepatitis B virus (HBV) infection. The aim of this study was to examine factors that predict posttreatment relapse. Comparison 22 patients who experienced relapse with 11 who did not after cessation of therapy showed that predictive factors for nonrelapse were hepatitis B e antigen seroconversion and duration of undetectable HBV DNA load (!0.7 log IU/mL), as determined by HBV real-time detection direct testing. However, 7 of 12 patients with seroconversion experienced relapse after cessation of therapy. Multivariate analysis revealed that the duration of an undetectable HBV DNA load was the only independent predictive factor for nonrelapse (odds ratio, 0.50; 95% confidence interval, 0.27-0.9). More-prolonged lamivudine therapy is required after seroconversion, and persistent duration of an HBV DNA level of !0.7 log IU/mL for 16 months can more accurately aid in the decision of when to stop lamivudine therapy. Lamivudine monotherapy is currently considered to be the best therapeutic option for patients with chronic hepatitis B, irrespective of hepatitis B e antigen (HBeAg) status [3] . It is generally accepted that the probability of viral resistance or virologic breakthroughs increases with the prolongation of lamivudine therapy by drug-resistant HBV mutants [4] [5] [6] [7] , possibly followed by acute hepatitis flares, hepatic decompensation, and possibly fatal hepatic failure [8] [9] [10] .
There have been reports of relapse after cessation of lamivudine monotherapy for hepatitis B virus (HBV) infection. The aim of this study was to examine factors that predict posttreatment relapse. Comparison 22 patients who experienced relapse with 11 who did not after cessation of therapy showed that predictive factors for nonrelapse were hepatitis B e antigen seroconversion and duration of undetectable HBV DNA load (!0.7 log IU/mL), as determined by HBV real-time detection direct testing. However, 7 of 12 patients with seroconversion experienced relapse after cessation of therapy. Multivariate analysis revealed that the duration of an undetectable HBV DNA load was the only independent predictive factor for nonrelapse (odds ratio, 0.50; 95% confidence interval, 0.27-0.9). More-prolonged lamivudine therapy is required after seroconversion, and persistent duration of an HBV DNA level of !0.7 log IU/mL for 16 months can more accurately aid in the decision of when to stop lamivudine therapy.
Hepatitis B virus (HBV) infection is a serious clinical problem worldwide that can lead to progressive liver disease and hepatocellular carcinoma [1] . Patients with genotype C infection have a more aggressive clinical phenotype than do those with genotype B infection, leading to poorer clinical outcomes [2] .
Lamivudine monotherapy is currently considered to be the best therapeutic option for patients with chronic hepatitis B, irrespective of hepatitis B e antigen (HBeAg) status [3] . It is generally accepted that the probability of viral resistance or virologic breakthroughs increases with the prolongation of lamivudine therapy by drug-resistant HBV mutants [4] [5] [6] [7] , possibly followed by acute hepatitis flares, hepatic decompensation, and possibly fatal hepatic failure [8] [9] [10] .
The Asia-Pacific Consensus on the Prevention and Management of Chronic Hepatitis B and C has recommended that full HBeAg seroconversion, defined as undetectable HBeAg and HBV DNA with reappearance of antibody to HBeAg (anti-HBe), may be considered a suitable end point for lamivudine therapy. On the basis of currently available data, it is also recommended that lamivudine therapy be maintained for 4-6 months after achieving HBeAg seroconversion to decrease the chance of posttreatment relapse [11] . This study evaluated the posttreatment durability of lamivudine and the predictive factors for cessation of lamivudine therapy without relapse for patients infected with HBV genotype C.
PATIENTS, MATERIALS, AND METHODS

Patients.
We analyzed 33 Japanese patients (24 men and 9 women; mean , years) with age ‫ע‬ SD 42.1 ‫ע‬ 9.6 chronic HBV infection after cessation of lamivudine therapy. All patients were administered 100 mg of lamivudine per day for у6 months (median, 12 months; range, 6-25 months). Once an undetectable serum HBV DNA level (!3.7 log genome equivalents [ LGE]/mL), as measured by transcription-mediated amplification-hybridization protection assay (TMA-HPA; Chugai Diagnostics Science), and a serum alanine aminotransferase (ALT) level of !40 IU/L (i.e., the upper limit of normal) had both been maintained for у6 months, lamivudine therapy was stopped prospectively in this study. In addition, for HBeAgpositive patients, HBeAg seroconversion was used as another criterion for stopping lamivudine therapy.
The patients sought care at Chukyo Hospital (Nagoya, Japan), Nagoya City University Hospital (Nagoya), and Kurume University Hospital (Kurume, Japan) during the period of 1996-2002. All patients provided written informed consent. Table 1 shows the pretreatment demographic and clinical characteristics of these 33 patients, who were positive for serum hepatitis B surface antigen (HBsAg). We investigated only patients who were infected with HBV genotype C. Five (15%) of 33 patients had liver cirrhosis, and 28 patients (85%) had chronic hepatitis. All patients were then clinically observed after cessation of lamivudine monotherapy (median duration of posttreatment monitoring, 13 months; range, 9-26 months).
Methods. Presence of serum HBsAg, HBeAg, and antiHBe (as measured by chemiluminescent enzyme immunoassay [Ortho Clinical Diagnostics]) and levels of HBV DNA and ALT were tested every month. HBV DNA was mainly measured using the TMA-HPA assay, which has a detection range of 3.7-8. 7 LGE/mL; when the HBV DNA level was undetectable (!3.7
LGE/mL), we performed a highly reproducible and sensitive HBV real-time detection direct test (HBV RTD-Direct test [SRL Inc.]) retrospectively, which combines the use of a DNA extraction system based on magnetic bead-coated polyclonal antiHBsAg. The HBV RTD-Direct test has a dynamic range of 0.7-8.0 log IU/mL. This procedure has a good correlation with the TMA-HPA assay and a higher sensitivity than TMA-HPA by ∼100 times [12] .
The end point was relapse of infection after cessation of therapy. Relapse was defined as reappearance of serum HBV DNA (13.7 LGE/mL, as measured using the TMA-HPA assay) plus a reactivation in the serum ALT to 180 U/L, as well as HBeAg seroreversion, while receiving treatment. Possible predictive factors were then analyzed.
Statistical evaluation. Data are expressed as mean ‫ע‬ SD or median (range). The primary focus of this analysis was to compare patients who experienced relapse (after cessation of lamivudine therapy, reappearance of serum HBV DNA [assessed by TMA-HPA] plus ALT level reactivation [i.e., a level of 180 IU/L], as well as HBeAg seroconversion while receiving treatment) with those who did not experience relapse. The Mann-Whitney U test and the x 2 test were used to analyze the data. The effects of age, sex, prevalence of cirrhosis, presence of HBeAg, pretreatment ALT level, pretreatment HBV DNA level, duration of lamivudine therapy, duration of an HBV DNA level of !3.7 LGE/mL, and duration of an HBV DNA level of !0.7 log IU/mL were assessed by logistic regression analysis. The cumulative relapse rate was calculated by Kaplan-Meier method, and the difference was determined by the log-rank test.
was considered to be statistically significant. For P ! .05 statistical analysis, we used Stata statistical software, version 7.0 (Stata).
RESULTS
All patients tested positive for HBV DNA and HBsAg before treatment; 19 patients (58%) tested positive for HBeAg. All patients also had abnormal ALT levels before receiving treatment. Nineteen patients (58%) had suppressed, undetectable HBV DNA levels (!0.7 log IU/mL), as measured by HBV RTD- LGE/mL (as measured using the TMA-HPA assay), total duration of lamivudine therapy, age, sex, presence of cirrhosis, presence of HBeAg, seronegative status, pretreatment ALT level, and pretreatment HBV DNA level were not significant (table 2). 7.2 ‫ע‬ 0.5 P p .021 Twelve patients (63%) had seroconversion to anti-HBe during treatment; however, 7 of these patients experienced relapse after cessation of lamivudine therapy. Among the patients who experienced HBeAg seroconversion, comparison of 7 patients who experienced relapse with 5 who did not revealed no significant differences; however, patients who experienced relapse had higher pretreatment HBV DNA levels, shorter durations of an HBV DNA level of !0.7 log IU/mL, and lower anti-HBe titers at the end of therapy (table 4) .
Multivariate analysis involving 8 factors indicated that a duration of an HBV DNA level of !0.7 log IU/mL (OR, 0.50; 95% CI, 0.27-0.93; ) remained the only independent P p .027 predictive factor for absence of posttreatment relapse. It is interesting to note that this analysis suggests that, when the duration of an HBV DNA level of !0.7 log IU/mL is extended by an additional month, the risk of relapse is reduced by onehalf (table 5) .
To analyze the relationship between the duration of an HBV DNA level of !0.7 log IU/mL and relapse in more detail, we classified patients into 2 groups: group A, consisting of 28 patients with a !6-months duration of HBV DNA levels of !0.7 log IU/mL before cessation of lamivudine therapy; and group B, consisting of 5 patients with a у6-months duration of HBV DNA levels of !0.7 log IU/mL before cessation of lamivudine therapy. The cumulative relapse rate was significantly higher in group A than in group B (79% vs. 0%; ) (figure 1). P p .006
DISCUSSION
Several clinical trials have shown that lamivudine is effective for improvement of transaminase levels and liver histology findings; however, the end point of the treatment has remained unclear because of relapse after cessation of therapy. In fact, 22 (67%) of 33 patients experienced relapse after cessation of lamivudine therapy in this study. Univariate analysis showed that HBeAg seroconversion and duration of an HBV DNA level of !0.7 log IU/mL was a prognostic indicator of no relapse; multivariate analysis showed that the duration of an HBV DNA level of !0.7 log IU/mL was a prognostic indicator of no relapse.
The TMA-HPA assay, which can detect HBV DNA levels of 3. 7-8.7 LGE/mL, is widely used for measuring HBV DNA levels in Japan; however, it was not enough to predict relapse after cessation of lamivudine therapy. By contrast, measurement of HBV DNA levels of 0.7-8.0 log IU/mL by using the HBV RTDDirect test, which combines the use of a DNA extraction based on magnetic beads and real-time PCR and is also a more sensitive method, revealed that a persistent low titer of HBV DNA log IU/mL (group A) and 5 patients with у6 months' duration of an HBV DNA level of !0.7 log IU/mL (group B) before cessation of lamivudine therapy. The relapse rate was significantly higher in group A than in group B ( ). P p .006 suppressed by lamivudine could lead to a lower relapse rate after cessation of treatment. Use of such a diagnostic kit is in line with the recommendations of previously published reports [13] [14] [15] .
In this study, the rate of HBe seroconversion was 63%, which is much higher than expected (it was 16% in an Asian study [16] ); the most likely reason for the high HBeAg seroconversion rate for the patients was the high baseline ALT level (median, 152 U/L), because it is well documented that high ALT levels predispose patients to earlier HBeAg seroconversion [17] . Although HBeAg seroconversion was predictive of absence of relapse, 7 (58%) of the 12 patients who had HBeAg seroconversion experienced relapse. This observation contrasts with the results from Western countries, in which IFN-a-and lamivudine-induced seroconversion is usually maintained after the cessation of therapy [18] [19] [20] [21] [22] [23] [24] . Song et al. [25] suggested that the high relapse rate may be caused by immune tolerance, which is caused by a long-standing viral infection. HBeAg seroconversion does not ensure prolonged suppression of HBV infection in areas where HBV is endemic and where parental transmission is common [26, 27] . Another factor may be the prevalence of different HBV genotypes among geographic regions. Genotypes C and D are associated with lower rates of response to IFN therapy than are genotypes B and A [2, 28] . In addition, the subtype adw is reported to be associated with a higher risk of lamivudine resistance than is the ayw subtype [2, 28] .
Recently, Dienstag et al. [18, 19] suggested that lamivudine therapy could be stopped after confirmed HBeAg loss or HBeAg seroconversion. However, our results indicate that moreprolonged lamivudine therapy is needed after seroconversion; the duration of lamivudine therapy should be modified by using results from the highly sensitive HBV RTD-Direct test and by determining pretreatment levels of serum HBV DNA, because these were predictive factors for relapse. On the basis of the results of this study, we suggest that, for patients in whom HBeAg seroconversion and persistent duration of an HBV DNA level of !0.7 log IU/mL of у6 months' duration, and in HBeAgnegative patients for whom the duration of an HBV DNA level of !0.7 log IU/mL is у6 months, cessation of therapy can be considered. For optimal monitoring for HBV viremia, the sensitive HBV RTD-Direct test could also have therapeutic implications, because it may allow not only early recognition of a virologic breakthrough, but also prediction of an early subsequent biochemical breakthrough. In summary, our data indicate that more-prolonged lamivudine therapy is probably required after HBeAg seroconversion, and duration of an undetectable HBV DNA level using the highly sensitive HBV RTD-Direct test, as opposed to other methods of HBV DNA detection, can more helpfully aid in the decision of when to stop lamivudine therapy.
